April 1, 2021 – B. Braun Interventional Systems Inc. (Bethlehem, PA) announced a U.S. collaboration with Infraredx, a Nipro Co. (Japan), to accelerate the FDA Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent Please ReX Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019. The companies are positioned to leverage shared resources to accelerate the initiation of the U.S. clinical trial of the SeQuent Please ReX to study the treatment of coronary in-stent restenosis (ISR), which is defined as the gradual re-narrowing of a coronary artery following stent implantation.